Bacterial virulence factors in neonatal sepsis: Group B streptococous

Current Opinion in Infectious Diseases

Volumn 17, Issue 3, 2004, Pages 225-229

  Herbert, Mark A ^a   Beveridge, Catriona J E ^a   Saunders, Nigel J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Group B streptococcus; Group B streptococcus whole genome sequence; Neonatal bacterial infections; Streptococcus agalactiae; Virulence factors

Indexed keywords

ADHESIN; BACTERIAL ENZYME; COMPLEMENT COMPONENT C5A; HEMOLYSIN; MEMBRANE PROTEIN; PEPTIDASE;

BACTERIAL GENOME; BACTERIAL METABOLISM; BACTERIAL STRAIN; BACTERIAL VIRULENCE; GENE CONTROL; GENE SEQUENCE; HUMAN; NEWBORN SEPSIS; PATHOGENICITY; REVIEW; SEROTYPE; STREPTOCOCCUS AGALACTIAE;

BACTEREMIA; BACTERIAL PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; INFANT, NEWBORN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; VIRULENCE; VIRULENCE FACTORS;

EID: 2542637078     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200406000-00009     Document Type: Review

References (51)

1. Paoletti LC, Kasper DL. Conjugate vaccines against group B streptococcus types IV and VII. J Infect Dis 2002; 186:123-126.
2. Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child 2003; 88:375-378. A good review of progress with conjugate vaccine development.
3. Glezen WP. Maternal vaccines. Prim Care 2001; 28:791-806; vi-vii.
4. Baker CJ, Rench MA, Mclnnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003; 21:3468-3472. This study provides evidence that vaccines are immunogenic when given in the pregnant state.
5. Lachenauer CS, Baker CJ, Baron MJ, et al. Quantitative determination of immunoglobulin G specific for group B streptococcal beta C protein in human maternal serum. J Infect Dis 2002; 185:368-374.
6. Nizet V, Ferrieri P, Rubens CE. Molecular pathogenesis of group B streptococcal disease in newborns. In: Stevens DL, Kaplan SL, editors. Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis. New York: Oxford University Press; 2000.
7. Nizet V, Rubens CE. 2000. Pathogenic mechanisms and virulence factors of group B streptococci. In: Fischetti VA, Novick RP, Ferretti JJ, et al., editors. The Gram positive pathogens. Washington DC: American Society for Microbiology; 2000. pp. 125-136.
8. Spellerberg B. Pathogenesis of neonatal Streptococcus agalactiae infections. Microbes Infect 2000; 2:1733-1742.
9. Glaser P, Rusniok C, Buchrieser C, et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol Microbiol 2002; 45:1499-1513.
10. Tettelin H, Masignani V, Cieslewicz MJ, et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A 2002; 99:12391-12396.
11. Overbeek R, Devine D, Vonstein V. Curation is forever: comparative genomics approaches to functional annotation. Targets - Drug Discov Today 2003; 2:138-146.
12. Kreikemeyer B, McIver KS, Podbielski A. Virulence factor regulation and regulatory networks in Streptococcus pyogenes and their impact on pathogen-host interactions. Trends Microbiol 2003; 11:224-232. This study reported that regulatory networks in GBS may parallel those already being uncovered in GAS.
13. Chaussee MS, Somerville GA, Reitzer L, Musser JM. Rgg coordinates virulence factor synthesis and metabolism in Streptococcus pyogenes. J Bacteriol 2003; 185:6016-6024. A knowledge of GAS virulence regulation may help in understanding GBS.
14. Mclver KS, Thurman AS, Scott JR. Regulation of mga transcription in the group A streptococcus: specific binding of Mga within its own promoter and evidence for a negative regulator. J Bacteriol 1999; 181:5373-5383.
15. Sperandio V, Torres AG, Jarvis B, et al. Bacteria-host communication: the language of hormones. Proc Natl Acad Sci U S A 2003; 100:8951-8956. A good review of bacterial-host interactions.
16. Zhou L, Lei XH, Bochner BR, Wanner BL. Phenotype microarray analysis of Escherichia coli K-12 mutants with deletions of all two-component systems. J Bacteriol 2003; 185:4956-4972.
17. Rajagopal L, Clancy A, Rubens CE. A eukaryotic type serine/threonine kinase and phosphatase in Streptococcus agalactiae reversibly phosphorylate an inorganic pyrophosphatase and affect growth, cell segregation, and virulence. J Biol Chem 2003; 278:14429-14441.
18. Grifantini R, Sebastian S, Frigimelica E, et al. Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A 2003; 100:9542-9547.
19. Egan SM. Growing repertoire of AraC/XylS activators. J Bacteriol 2002; 184:5529-5532.
20. Novak R, Charpentier E, Braun JS, Tuomanen E. Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin. Mol Cell 2000; 5:49-57.
21. Yoshida A, Kuramitsu HK. Multiple Streptococcus mutans genes are involved in biofilm formation. Appl Environ Microbiol 2002; 68:6283-6291.
22. Koskiniemi S, Sellin M, Norgren M. Identification of two genes, cpsX and cpsV, with putative regulatory function on capsule expression in group B streptococci. FEMS Immunol Med Microbiol 1998; 21:159-168.
23. Shelver D, Rajagopal L, Harris TO, Rubens CE. MtaR, a regulator of methionine transport, is critical for survival of group B streptococcus in vivo. J Bacteriol 2003; 185:6592-6599. Studies of GBS regulatory networks may reveal novel means of preventing GBS disease.
24. Mascher T, Zahner D, Merai M, et al. The Streptococcus pneumoniae cia regulon: CiaR target sites and transcription profile analysis. J Bacteriol 2003; 185:60-70. A good example of investigating a regulator.
25. Graham MR, Smoot LM, Migliaccio CA, et al. Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modelling. Proc Natl Acad Sci U S A 2002; 99:13855-13860.
26. Spellerberg B, Rozdzinski E, Martin S, et al. Rgf encodes a novel two-component signal transduction system of Streptococcus agalactiae. Infect Immun 2002; 70:2434-2440.
27. Jones AL, Needham RH, Rubens CE. The delta subunit of RNA polymerase is required for virulence of Streptococcus agalactiae. Infect Immun 2003; 71:4011-4017.
28. Jones AL, Knoll KM, Rubens CE. Identification of Streptococcus agalactiae virulence genes in the neonatal rat sepsis model using signature-tagged mutagenesis. Mol Microbiol 2000; 37:1444-1455.
29. Johri AK, Padilla J, Malin G, Paoletti LC. Oxygen regulates invasiveness and virulence of group B streptococcus. Infect Immun 2003; 71:6707-6711. Gene products that enhance the destructiveness or invasiveness of GBS may be upregulated during environmental transitions.
30. Courtney HS, Hasty DL, Dale JB. Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Ann Med 2002; 34:77-87.
31. Beckmann C, Waggoner JD, Harris TO, et al. Identification of novel adhesins from group B streptococci by use of phage display reveals that C5a peptidase mediates fibronectin binding. Infect Immun 2002; 70:2869-2876.
32. Poyart C, Pellegrini E, Marceau M, et al. Attenuated virulence of Streptococcus agalactiae deficient in D-alanyl-lipoteichoic acid is due to an increased susceptibility to defensins and phagocytic cells. Mol Microbiol 2003; 49:1615-1625.
33. Tyrrell GJ, Kennedy A, Shokoples SE, Sherbume RK. Binding and invasion of HeLa and MRC-5 cells by Streptococcus agalactiae. Microbiology 2002; 148:3921-3931.
34. Adderson EE, Takahashi S, Wang Y, et al. Subtractive hybridization identifies a novel predicted protein mediating epithelial cell invasion by virulent serotype III group B Streptococcus agalactiae. Infect Immun 2003; 71:6857-6863.
35. Nizet V. Streptococcal beta-hemolysins: genetics and role in disease pathogenesis. Trends Microbiol 2002; 10:575-580.
36. Ring A, Braun JS, Pohl J, et al. Group B streptococcal beta-hemolysin induces mortality and liver injury in experimental sepsis. J Infect Dis 2002; 185:1745-1753.
37. Doran KS, Chang JC, Benoit VM, et al. Group B streptococcal beta-hemolysin/cytolysin promotes invasion of human lung epithelial cells and the release of interleukin-8. J Infect Dis 2002; 185:196-203.
38. Doran KS, Liu GY, Nizet V. Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis. J Clin Invest 2003; 112:736-744.
39. Okazaki N, Osawa R, Suzuki R, et al. Novel observation of hot-cold-hot hemolysis exhibited by group B streptococci. J Clin Microbiol 2003; 41:877-879.
40. Lang S, Palmer M. Characterization of Streptococcus agalactiae CAMP factor as a pore-forming toxin. J Biol Chem 2003; 278:38167-38173 This paper presents an advance in understanding the CAMP factor.
41. Harris TO, Shelver DW, Bohnsack JF, Rubens CE. A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis, and cleavage of human fibrinogen. J Clin Invest 2003; 111:61-70.
42. Yildirim AO, Fink K, Lammler C. Distribution of the hyaluronate lyase encoding gene hy/B and the insertion element IS1548 in streptococci of serological group B isolated from animals and humans. Res Vet Sci 2002; 73:131-135.
43. Navarre WW, Schneewind O. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev 1999; 63:174-229.
44. Bolduc GR, Baron MJ, Gravekamp C, et al. The alpha C protein mediates internalization of group B streptococcus within human cervical epithelial cells. Cell Microbiol 2002; 4:751-758.
45. Areschoug T, Stalhammar-Carlemalm M, Karlsson I, Lindahl G. Streptococcal beta protein has separate binding sites for human factor H and IgA-Fc. J Biol Chem 2002; 277:12642-12648.
46. Cheng Q, Stafslien D, Purushothaman SS, Cleary P. The group B streptococcal C5a peptidase is both a specific protease and an invasin. Infect Immun 2002; 70:2408-2413.
47. Cheng Q, Debol S, Lam H, et al. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B streptococci from lungs of infected mice. Infect Immun 2002; 70:6409-6415.
48. Franken C, Haase G, Brandt C, et al. Horizontal gene transfer and host specificity of beta-haemolytic streptococci: the role of a putative composite transposon containing scpB and Imb. Mol Microbiol 2001; 41:925-935.
49. Jarva H, Jokiranta TS, Wurzner R, Meri S. Complement resistance mechanisms of streptococci. Mol Immunol 2003; 40:95-107. An excellent review of complement avoidance mechanisms in streptococci.
50. Jones AL, Needham RH, Clancy A, et al. Penicillin-binding proteins in Streptococcus agalactiae: a novel mechanism for evasion of immune clearance. Mol Microbiol 2003; 47:247-256.
51. Hughes MJ, Moore JC, Lane JD, et al. Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun 2002; 70:1254-1259.